Serum Exosomal MicroRNAs as Potential Biomarkers for Centrally Mediated Abdominal Pain Syndrome.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Churchill Livingstone Country of Publication: United States NLM ID: 100898657 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-8447 (Electronic) Linking ISSN: 15265900 NLM ISO Abbreviation: J Pain Subsets: MEDLINE
    • Publication Information:
      Original Publication: Philadelphia, PA : Churchill Livingstone, c2000-
    • Subject Terms:
      MicroRNAs*/blood ; Exosomes*/metabolism ; Biomarkers*/blood ; Abdominal Pain*/blood ; Abdominal Pain*/diagnosis; Humans ; Male ; Female ; Adult ; Middle Aged
    • Abstract:
      Centrally mediated abdominal pain syndrome (CAPS) has generated a heavy disease burden worldwide. This study aimed to explore the serum exosomal microRNAs (miRNAs) as potential diagnostic biomarkers for CAPS. From September 2022 to October 2023, 97 patients with CAPS and 96 healthy subjects were enrolled. Differentially expressed serum exosomal miRNAs between patients with CAPS and healthy controls were identified by high-throughput sequencing and quantitative real-time polymerase chain reaction. The receiver operating characteristic curves and multivariate logistic regression analysis were used to evaluate the diagnostic value of the serum exosomal miRNAs. MiR-6850-5p, miR-194-5p, miR-199a-3p, and miR-4525 were significantly downregulated in serum exomes of CAPS patients compared with healthy controls, which yielded the area under curve (AUC) values of .914 (95% confidence interval (CI), .873-.954), .767 (95% CI, .695-.839), .617 (95% CI, .527-.708), and .561 (95% CI, .465-.656), respectively, to distinguish CAPS patients from healthy subjects. And AUC of the integration of the above 4 miRNAs was .931 (95% CI, .896-.966). Multivariate logistic regression indicated that hsa-miR-6850-5p (odds ratio (OR) = .046, P < .001), anxiety (OR = 7.670, P = .025), and depression (OR = 22.967, P = .008) were the independent predictors of CAPS. Serum exosomal miR-6850-5p is a promising diagnostic biomarker for CAPS. PERSPECTIVE: This study may be the first to explore serum exosomal miRNAs as new diagnostic biomarkers for CAPS, and the findings may help clinicians to access comprehensive understanding and accurate diagnosis of CAPS.
      (Copyright © 2024 United States Association for the Study of Pain, Inc. Published by Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Centrally mediated abdominal pain syndrome; disorder of gut-brain interaction; exosome; functional gastrointestinal disorder; microRNA
    • Accession Number:
      0 (MicroRNAs)
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20240627 Date Completed: 20241017 Latest Revision: 20241017
    • Publication Date:
      20241018
    • Accession Number:
      10.1016/j.jpain.2024.104616
    • Accession Number:
      38936748